Hepatocellular carcinoma (HCC) is the most common visceral neoplasms with its heterogeneity and high rate of recurrence. HCC is characterized to be delayed diagnosis and the development of resistant disease. However, the molecular mechanism for HCC pathogenesis and progression remains largely unknown. Here, we demonstrated that ubiquitin-specific protease 14 (USP14) is highly expressed in HCC samples, and the higher expression of USP14 is positively correlated with poor prognosis. Interestingly, USP14 is involved in the maintenance of HIF1-α stability to activate HIF1-α-induced transactivation via its deubiquitinase activity. USP14 depletion or its specific inhibitor IU1 treatment decreased cell proliferation, invasion, migration, and Vascular Mimicry (VM) formation even under hypoxia conditions in HCC cell lines. Moreover, we provided the evidence to show that knockdown of USP14 or USP14 inhibitor (IU1) treatment inhibited tumor growth in tumor-bearing nude mice. Our findings suggest that USP14 maintains HIF1-α stability through its deubiquitination activity, providing a potential biomarker for the early diagnosis and therapy of HCC.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is one of the most serious carcinomas, with a 5-year survival rate is 14–18%. HCC is the third cause of cancer mortality worldwide [1]. Despite the emergence of promising treatment strategies, most of the patients had advanced to the middle and late stages due to the difficulty in early diagnosis for HCC [2]. Even with surgical treatment, the recurrence rate within 5 years was as high as 40–60% [3]. Therefore, it is urgent to gain insight into the molecular mechanism of tumorigenesis and progression of HCC to explore potential therapeutic targets for HCC patients.

Hypoxia is a hallmark for solid tumors microenvironment, which is attributed to the vasculature reformation and metabolic reprogramming [4]. Hypoxia-induced factor (HIF-1) is the major regulator of oxygen homeostasis. HIF-1 consists of two subunits: one is oxygen-sensitive HIF-1α subunit, assisting the cellular adaptive response to hypoxia, the other is the constitutively expressed HIF-1β subunit [5]. HIF-1α as a transcriptional regulator is recruited to the hypoxia response element (HRE) of target genes to induce the transcription of a series of target genes, including VEGF, MMP2, MET, TWIST and so on [6]. The previous study has shown that HIF-1α-mediated genes give rise to angiogenesis and metastasis, which are crucial for the development and progression of HCC [7].

HIF-1α degradation has been reported to be triggered by ubiquitination via a von Hippel-Lindau (VHL)-containing E3 ubiquitin ligase [8]. It has been mentioned that some proteins involved in the maintenance of HIF-1α stability play crucial roles in tumorigenesis and progression of HCC. Ubiquitin-specific protease 22 (USP22) stabilizes HIF1-α to promote hypoxia-mediated HCC stemness and glycolysis by its deubiquitinase activity [9]. CDC20 as a cell cycle regulator mediates PHD3 degradation to increase the stability of HIF1-α in HCC [10]. Thus, understanding well the molecular mechanism underlying the modulation of HIF1-α stability would be essential for finding the potential therapeutic targets for HCC.

Ubiquitin-specific protease 14 (USP14) as a member of the Ubiquitin-specific proteases (USP) protein family interacts with the 26S proteasome complex [11] and enhances its deubiquitination by reversibly binding to the Rpn1 in the proteasome 19S regulating particle [12]. USP proteases are the antagonists of E3 ligases to be increasingly recognized as potential targets in cancer treatment [13]. IU1 is one of the selective small-molecule inhibitors of deubiquitination activity of USP14, and IU1 is able to accelerate proteolysis in cells [14]. It has been demonstrated that a specific USP14 and UCH37 inhibitor b-AP15 inhibits the growth of tumor with P53 deficiency [15]. Moreover, inhibition of USP14 increased AR degradation and suppressed the AR-mediated signalling pathway to enhance the sensitivity of AR-positive breast cancer to AR antagonist (enzalutamide) [16]. USP14 plays an indispensable role in hepatosteatosis through the stabilization of FASN [17]. However, the function of USP14 on HCC progression is still elusive.

In this study, our results have shown that USP14 participates in the maintenance of HIF1-α stability and enhances HIF1-α-induced transcriptional activity via its deubiquitination activity in HCC cell.
In addition, USP14 is highly expressed in clinical HCC samples, and higher expression of USP14 is positively correlated with the poor prognosis in HCC. USP14 depletion or USP14 specific inhibitor IU1 significantly suppresses cell growth, migration, and VM formation in HCC. Moreover, we provided the evidence to demonstrate that knockdown of USP14 or IU1 treatment inhibited tumor growth in mice. Our findings indicate that USP14 as a deubiquitinase is involved in maintaining HIF1-α stability and enhancement of HIF1-α activity, suggesting USP14 would be a potential diagnosis biomarker and therapeutic target for HCC.

RESULTS
USP14 is highly expressed in HCC samples, and the higher expression of USP14 is positively correlated with poor prognosis

We first analyzed The Cancer Genome Atlas (TCGA) data using the UALCAN online tool (http://ualcan.path.uab.edu/index.html). The results showed that USP14 mRNA expression was significantly higher in primary HCC tissues than that in normal liver tissues (Figure S1A). Additionally, USP14 protein is highly expressed in HCC specimens compared with that in normal liver samples according to The Human Protein Atlas (http://proteinaLAS.org/), which is a public repository of immunohistochemistry data (Figure S1B). UALCAN online tool analysis demonstrated a significant correlation between USP14 mRNA expression and clinical cancer stages and histological grades (Figure S1C, D). Moreover, an online Kaplan-Meier Plotter analysis tool (http://kmplot.com) showed that HCC patients with high USP14 expression had significantly decreased overall survival and relapse-free survival (Figure S1E, F). Consistent with the above-mentioned bioinformatics online database analysis, western blotting analysis demonstrated that USP14 protein was highly expressed in 34 pairs of fresh clinical HCC samples (T) compared with that in the adjacent non-tumor tissues (N) (Fig. 1A, B). Immunohistochemistry (IHC) results containing 90 pairs of HCC samples demonstrated that USP14 was highly expressed in HCC tissues compared with those in the adjacent tissues (Fig. 1C, D).

The HCC patients were divided into the high USP14 and low USP14 groups according to the IHC score. The median IHC score of 6.0 was chosen as the cut-off value to define the high and low expression of USP14. Our results showed that high USP14 expression was positively associated with the differentiation of HCC, but has no relationship with other clinicopathological features, including age, gender, cirrhosis, tumor size, perihepatic organ invasion, vascular invasion, lymph node metastasis, and TNM (tumor, lymph node, and metastasis) state (Fig. 1E, Table S1). The prognostic value of USP14 was further explored. Our results showed that highly expression of USP14 was positively correlated with the poor prognosis (p = 0.0071, HR = 1.985) (Fig. 1F). The median overall survivals in high USP14 and low USP14 groups were 22 and 44 months, respectively. Multivariate analyses using the Cox regression model revealed USP14 as an independent prognostic factor for overall survival in HCC (Table S2). Collectively, these data suggest that USP14 is highly expressed in HCC samples, and higher expression of USP14 is positively correlated with malignant progression and the poor prognosis in HCC.

USP14 enhances HIF1-α-mediated transactivation in HCC cells

In order to explore the mechanism underlying the function of USP14 in HCC progression, we turned to analyze the data from the GEPIA database (http://gepia.cancer-pku.cn). The data suggest that mRNA expression of USP14 was positively correlated with that of HIF1-α target genes, including MET, VEGF-A, MMP2, and TGFB3 (Fig. 2A), but not TWIST and EPO (Figure S2A, B). We thus supposed that USP14 might be involved in the modulation of HIF1-α-induced transactivation. A luciferase assay was then performed under normoxia and hypoxia conditions to determine the regulation function of USP14 on HIF1-α action. Our results demonstrated that HIF1-α-mediated transcriptional activity was enhanced by USP14 under hypoxia conditions in HCCLM3 cells (Fig. 2B). Furthermore, overexpression of USP14 significantly upregulated the transcription of the endogenous HIF1-α target genes, including MET, VEGF-A, and MMP2 (Fig. 2C). Taken together, our results suggest that USP14 enhances HIF1-α-mediated transactivation.

USP14 maintains HIF1-α stability via its deubiquitination activity

Having established that USP14 as a deubiquitinase enhances the transcriptional activity of HIF1-α, we thus turned to analyze the mechanism underlying the modulation function of USP14 on HIF1-α action. As shown in Fig. 2D, CoCi2- induced hypoxia significantly increased HIF1-α protein expression compared to the normoxic state. USP14 depletion significantly decreased HIF1-α protein level, but not HIF1-α mRNA level in HCC cells, suggesting that USP14 may be involved in the maintenance of HIF1-α stability (Fig. 2E, F, Figure S2D). Furthermore, the results in co-IP experiments showed that the endogenous USP14 interacted with HIF1-α in HCCLM3 and Huh-7 cells under hypoxia conditions induced by CoCi2 (Fig. 3A).

To further examine the influence of USP14 on HIF1-α stability in hypoxia, HCC cells were treated with protein synthesis inhibitor, cycloheximide (CHX). Knockdown of USP14 or USP14 inhibitor specific for its deubiquitination activity (IU1) [18, 19] accelerated the degradation of HIF1-α protein in HCCLM3 cells with the treatment of CoCi2 (Fig. 3B and Figure S3C). Moreover, the ubiquitination assay demonstrated that the ubiquitination level of HIF1-α was significantly increased by USP14 depletion or IU1 treatment in HCCLM3 and Huh-7 cells (Fig. 3C, D). While the ectopic expression of USP14 decreased the ubiquitination level of HIF1-α (Fig. 3E).

Next, we want to determine the specific type of HIF1-α polyubiquitin influenced by USP14. Under hypoxia conditions induced by CoCi2, HCCLM3 cells were separately transfected with Flag-USP14 and different ubiquitins (K0-, K48-, or K63-only ubiquitin-HA tagged). Then, HIF1-α proteins were purified and subjected to western blot analysis using an anti-HA antibody. Our results demonstrated that K48- and K63- linked ubiquitination on HIF1-α were substantially decreased by the overexpression of USP14 (Fig. 3F). Taken together, our results suggest that USP14 participates in the maintenance of HIF1-α stability by its deubiquitinase activity in hypoxia.

USP14 increases cell proliferation in HCC cell lines

To assess the biological function of USP14 in the development and progression of HCC, we firstly examined USP14 protein expression in a panel of immortalized hepatocyte and HCC cell lines. Compared with the immortalized HL-7702 hepatocyte cell line, USP14 is significantly higher in Huh-7 cells and moderately higher in PLC/PRF/5, HCCLM3, and BEL-7402 cells, but weakly expressed in SMMC-7721 and Hep G2 cells (Figure S3A). We performed a knockdown of USP14 expression in Huh-7 and HCCLM3 cells using shRNA and verified USP14 knockdown efficiency by western blot (Figure S3B). Growth curves analysis showed that USP14 depletion and its inhibitor IU1 inhibited cell proliferation under normoxia and hypoxia conditions (Fig. 4A, B). Moreover, compared with control, 50 μM IU1 administration significantly reduced cell viability in time-dependent manners (Fig. 4A, B).

Consistently, colony formation experiments demonstrated that knockdown of USP14 formed a lower number of colonies than that of control (Fig. 4C). Additionally, in USP14-silenced HCC HCCLM3 cells, the expression plasmid of HIF1-α was transfected.
Fig. 1  Upregulation of USP14 predicts poor clinical outcome in patients with HCC. A The protein expression of USP14 in HCC tissues were examined by western blot. N stands for the adjacent non-tumorous tissues, T stands for HCC tissues. B The representative images and the statistical analysis were indicated. C, D The expression of USP14 in adjacent non-tumorous tissues, HCC tissues with different levels of differentiation was detected by IHC. Scale bar, 100 μM. E The representative images and the IHC scores were shown. F The clinical significance of USP14 expression in overall survival was evaluated in the TMA-based cohort by Kaplan–Meier survival analyses.
The above results suggested USP14 promotes HCC cell proliferation partially in a HIF1-α-dependent manner.

**USP14 promotes cell migration, invasion, and VM formation in HCC cells**

Hypoxia is a common phenomenon in HCC due to the large consumption of oxygen and energy, which affects the metastasis,
Fig. 3 USP14 interacts with HIF1-α and participates in deubiquitination of HIF1-α. A Immunoprecipitation experiments showed that endogenous USP14 interacted with HIF1-α in both HCCLM3 and Huh-7 cells. Cells were treated with or without CoCl2 (100 mM). B HCCLM3 cells stably knocking down of USP14 or IU1 addition were treated with cycloheximide (CHX) as indicated. Western blot was used to detect HIF1-α and USP14 protein levels. C The control and USP14 knockdown HCCLM3 and Huh-7 cells were treated with MG132 at 20 μM for 6 h. The cell lysates were then immunoprecipitated with anti-HIF1-α, and the immunocomplexes were immunoblotted with anti-His. D Protein lysates were collected from HCCLM3 cells treated with IU1 for 48 h. A co-immunoprecipitation assay was performed using HIF1-α antibody and immunoblotted with anti-His. Cells were exposed to MG132 (20 μM) for 6 h before harvest. E HCCLM3 cells were transfected with Flag-USP14 or empty vector and followed by immunoprecipitation with anti-HIF1-α. F HCCLM3 cells with ectopic expression of Flag-USP14 and HA-tagged different ubiquitin mutants, including K0 (lysineless), K48 (only K48-linked-Ub), and K63 (only K63-linked-Ub) were treated with MG132 (20 μM) for 6 h as indicated. The cell lysates were immunoprecipitated by using anti-HIF1-α. The ubiquitination levels of HIF1-α were detected using anti-HA. All the above hypoxic environment refers to hypoxia-induced by CoCl2 at 100 μM.
In the hypoxic condition, HIF-1α protein is accumulated and induces the activity of its downstream vascular endothelial growth factor (VEGF) genes, thereby promoting VM formation [21]. HIF-1α was reported to induce vasculogenic mimicry formation in several human cancer cells [22, 23]. We thus turned to examine the effects of USP14 on migratory and invasive behaviors of HCC cells. Firstly, cell migration and invasion in Huh-7 cells were markedly inhibited under normoxia conditions by IU1 supplementation at concentrations of 50 and 100 μM (Fig. 5A). Transwell assay demonstrated...
that knockdown of USP14 showed a similar effect both in normoxia and hypoxia (Fig. 5B). Subsequent rescue assay showed that the inhibition was partially reversed by HIF1-α (Fig. 5C).

Vasculogenic mimicry (VM), an abnormal blood supply pattern, is associated with poor patient prognosis and is considered as a loophole for antiangiogenetic therapy and is critical for tumor growth and metastasis [24]. To investigate the function of USP14 in VM, we used a Matrigel-based tube formation assay. As shown in Fig. 6A, knockdown of USP14 and administration with 50 μM IU1 remarkably inhibited tube formation. Moreover, the suppression of VM induced by USP14 depletion was partially attenuated by the restoration of HIF1-α expression (Fig. 6B). These findings indicated that USP14 serves upstream of HIF1-α to regulate HCC progression.

**USP14 depletion or IU1 treatment suppresses HCC cell growth in mice**

To further confirm the proliferation potential of USP14, the control and USP14-silenced HCCLM3 cells were subcutaneously injected into nude mice (Fig. 7A, B). The size of xenograft
tumors from USP14 stable knockdown cells were much smaller than those formed by the control cells (Fig. 7C). Additionally, the tumor volume from shUSP14 cells demonstrated a lower growth rate than tumors from the shCtrl cells (Fig. 7D). Moreover, the tumor weight of the shUSP14 group was markedly lower than that of the control group (Fig. 7E). However, no obvious body weight loss happened in the two groups (Fig. 7F). Subsequently, the level of USP14, Ki67, and HIF1-α were evaluated using immunochemical staining. We found that the expression of USP14, Ki67, and HIF1-α, which promote proliferation, were decreased in the shUSP14 group (Fig. 7G). Collectively, these data demonstrated that USP14 promoted HCC proliferation and tumor growth.

To further verify whether ablation of USP14 or/and a selective deubiquitination activity inhibitor of USP14 (IU1) could restrain HCC growth in animals, we implanted subcutaneously USP14-depleted HCCLM3 cells stably expressing USP14-specific shRNA (shUSP14) or control shRNA (shCtrl) and monitored tumor growth as they were treated with IU1 or vehicle (Figure S4A, B). Importantly, a synergic effect of oral administration of IU1 in combination with lentivirus-mediated USP14 knockdown on tumor growth inhibition was observed upon co-treatment of the two different ways to inhibit USP14 for 14 days (Fig. 8A). Tumor volumes and tumor weight exerted remarkably declined in the combination therapy as compared with the lentivirus-mediated USP14 knockdown or IU1 alone treatment (Fig. 8B, C). However, no obvious body weight loss was observed in each experimental group (Figure S4C). Furthermore, immunohistochemical experiments demonstrated that the protein levels of USP14, HIF1-α, and Ki67 were decreased in the IU1/ shUSP14 combined group compared with the signal treatment (Fig. 8D).

**DISCUSSIONS**

It has been widely accepted that solid cancers are characterized by their limited oxygenation (called hypoxia) [25]. As an important metabolic organ, the local partial pressure of oxygen in the liver can even be as low as 0.8% [26]. HIF1-α, a crucial regulator of oxygen homeostasis [27], is associated with metastasis [28], angiogenesis [29], and sorafenib resistance [30] in HCC. USP14 has been recognized as a key regulator of proliferation [31], apoptosis [32] in tumor [33]. However, the downstream molecules of USP14 are still poorly understood. In this study, our results have demonstrated that USP14 interacts with HIF1-α, and co-activates HIF1-α-induced transcriptional activity via its deubiquitination activity in HCC (Fig. 8E). Previous researches reported an obvious negative correlation between USP14 expression and survival time of patients with non-small-cell lung cancer [34]. Consistent with the previous findings of USP14 in hepatocellular carcinoma [35], our study has demonstrated the key role of USP14 in determining the clinical severity and prognosis of patients, and thus to explore the anticancer efficacy of USP14 inhibitor IU1 as a potential hepatocellular carcinoma therapeutic agent in vivo and in vitro. USP14 acts as a deubiquitinating enzyme to avoid the degradation of substrate proteins. In normal liver tissues (normoxia dominated), the USP14 protein level is lower than that of tumor tissues, and HIF1-α is lower expressed. When hepatocellular carcinoma occurs, the USP14 protein level is abnormally increased in HCC tissues. With the rapid growth of HCC, the tumor cells...
would respond to the adverse effects of hypoxia, HIF1-α protein level dramatically increases, at this time, highly expressed USP14 would be involved in the maintenance of HIF1-α protein stability. The accumulation of excess HIF1-α protein enhances the transcription of downstream target genes, which in turn enhances the malignant biological behaviors such as proliferation, invasion and metastasis, and neovascularization of hepatocellular carcinoma cells, leading to tumor progression. Excitingly, we revealed a novel mechanism by which hepatocellular carcinoma tissues tolerate hypoxic adversities and maintain sustained malignant biological behavior through the modulation function of USP14 on HIF1-α-mediated transactivation. Moreover, it has been reported that the expression of HIF1-α is positively correlated with that of HIF1-α target genes, including SNAIL and TWIST, which are involved in tumor metastasis in HCC [36]. Our results demonstrated that the higher protein level of USP14 was not only positively correlated with that of the HIF1-α, but also closely related to the clinical stage, tumor differentiation, and patient prognosis of HCC. These results imply a rational basis for targeting the USP14-HIF1-α axis to control HCC progression.

Deubiquitinase is usually considered that it can remove ubiquitin marks from substrates to restrain the substrates from

**Fig. 7 USP14 depletion suppresses HCC cell growth in mice.** A BALB/c nude mice were subcutaneously injected with HCC HCCLM3 cells stably expressing either human USP14-specific shRNA (left) or control shRNA (right). Representative tumor xenograft images (B), tumor volume (C), tumor weighed (D), and mouse body weight (E) were shown ***P < 0.001; ****P < 0.0001; ns = no significance. F Immunohistochemistry staining for USP14, HIF1-α, and Ki67. Scale bar, 100 μM.
Among the known ubiquitin linkage-type, including K6, K11, K27, K29, K33, K48, and K63, K48 is well known for tagging protein substrates for proteasomal degradation, while K63 has been reported to play roles in both transcriptional regulation and protein degradation. In the present study, we provided evidence that both K48- and K63-linked polyubiquitination on HIF1-α were significantly reduced by overexpression of USP14, suggesting that USP14 is involved in the maintenance of HIF1-α stability by triggering K48- and K63-linked deubiquitination on HIF1-α via its deubiquitination activity. On the other hand, our results also indicate that USP14 may modulate HIF1-α action through K63-linked deubiquitination beyond protein degradation. It would be fantastic to find other biological functions for K63-linked deubiquitination on HIF1-α by USP14 in future work.

Traditionally, the rapid breakdown (proteolysis) of HIF1-α protein is closely related to the microenvironmental oxygen content. Recently, increasing evidence suggests that HIF1-α levels accumulate even in normoxia, when tumor suppressor genes such as Phosphatase and Tensin homolog (PTEN) or p53 are suppressed.
or oncogenes such as RAS and phosphoinositide 3-kinase (PI3K) are activated [42]. The results in this study suggested that USP14 is upregulated and plays a carcinogenic role in HCC, including promoting proliferation, invasion, and metastasis. Therefore, the regulatory function of USP14 on HIF1-α action revealed under hypoxia conditions in this work may also be applicable for the normoxic state in tumor cells.

Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation by inhibiting serine/threonine kinase isoforms of Raf, Raf-1, and B-Raf, leading to the inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) signaling pathways, decreased expression of cyclin D1 and cell cycle arrest. As a first-line drug approved for therapy in patients with advanced liver cancer by the FDA, sorafenib was once widely used for HCC therapy, however, the effect of sorafenib on the treatment of HCC patients is still unsatisfactory [43]. The possible mechanism for the resistance of sorafenib treatment has been considered that inhibition of tumor angiogenesis by blocking VEGF signal further exacerbates hypoxia within the tumor [44]. Our results showed that USP14 was involved in the upregulation of HIF1-α-induced expression of VEGF, MMP2, or MCT. Additionally, USP14 depletion and its inhibitor IU1 significantly inhibited cell proliferation, migration, and angiogenesis in HCC, suggesting that USP14 might be a potential therapeutic target for HCC. Thus, the combined application of sorafenib and USP14 inhibitors will hopefully enhance the sensitivity of sorafenib. However, before targeting USP14 strategy applied to clinical practice, the following issues need to be carefully considered and further explored: 1) does USP14 have an extra effect on other HIF family members HIF1-β? 2) what potential side effects following the systemic administration of USP14 inhibitors IU1, especially in the cardio, cerebral, renal and reductive system. A reasonable solution to the above issues will facilitate improving the therapeutic effect of USP14 inhibitor in HCC in the future.

Taken together, our findings suggest a novel mechanism and functional link between USP14 and HIF1-α in the malignant biological behavior of HCC, providing a novel therapeutic target for HCC therapy.

MATERIALS AND METHODS

Chemical reagents and plasmid constructs

IU1 (S7134) was obtained from Selleckchem (Houston, USA). Cycloheximide (CHX) was purchased from Sigma-Aldrich and MG132 was purchased from Abmole. Dimethylsulphoxide (DMSO) was used to dissolve these chemicals. Cells were plated at a density of 3 × 10³ cells per well in 96-well plates. MTS assay (CellTiter 96Aqueous One Solution reagent, Promega, USA) was employed to determine the number of viable cells over 6 days. In brief, cells were plated at a density of 3 × 10³ cells per well in 96-well plates. MTS reagent was added to each well of the plate at different time points, and the plates were incubated for 4 h in an incubator, and absorbance was measured at 490 nm. Each cell group was plated in three duplicate wells.

Cell culture

Human HCC cell lines (BEL-7402, HCCLM3, Huh-7, PLC/PRF/5, HepG2, and SMMC-7721) and normal liver cells HL-7702 were purchased from the Cell Resource Center, Chinese Academy of Science Committee (Shanghai, China). HEK293 cells were kindly provided by Professor Yujie Hu from Abmole. Dimethylsulphoxide (DMSO) was used to dissolve these chemicals. Cells were plated at a density of 3 × 10³ cells per well in 96-well plates. MTS assay (CellTiter 96Aqueous One Solution reagent, Promega, USA) was employed to determine the number of viable cells over 6 days. In brief, cells were plated at a density of 3 × 10³ cells per well in 96-well plates. MTS reagent was added to each well of the plate at different time points, and the plates were incubated for 4 h in an incubator, and absorbance was measured at 490 nm. Each cell group was plated in three duplicate wells.
For colony formation assay, 5 × 10^5 cells were maintained in medium 10% FBS supplemented for 14 days. Cell cultures were then fixed with methanol and stained with Coomassie blue dye.

For the FACS assay, the cells were grown in six-well plates for 24 h, then were dissociated with trypsin, resuspended in PBS, and fixed in ice-cold 70% ethanol. Next, the cells were incubated with 50 μg/ml PI, 100 μg/ml RNase and propidium iodide (PI; Invitrogen) for 30 min at 4 °C for 1 h. The cell-cycle analysis was performed by a FACS flow cytometer (BD Biosciences C6). The software for analysis cell cycle is ModFit.

For 3D culture, matrigel (BD Biosciences, USA) was used to coat the 96-well plate and polymerized it at 37 °C for 4 h to solidify the Matrigel. 1 × 10^4 HCC cells (30 μl/well) were cultured in the Matrigel-coated plates for 24 h. The formation of capillary-like structures was observed under phase-contrast microscopy (200× magnification). Each experiment was performed in triplicate.

Transwell migration and invasion assay

Cell migration was assessed using a 24-well transwell chamber (8.0 μm pore size filter; Corning, Canton, NY). Cells were harvested and resuspended in a serum-free culture medium. The cell suspension (200 μl, 6 × 10^5 cells) was added to each upper chamber, and each lower chamber was filled with 600 μl 10% serum medium. After 24 h incubation at 37 °C, chambers were gently washed twice with PBS, methanol fixed and then Crystal Violet Staining Solution (Solarbio, Beijing, China) stained. Cells that had traversed the filter to the lower chamber were counted microscopically (200×) in three different fields per filter. For the invasion assay, the cell suspension was added to Matrigel Matrix (Corning, Canton, NY, USA) pre-coated transwells and incubated for 4 h at 37 °C, and the assay was conducted using the same procedure as the migration assay.

Nude mouse xenograft growth

BALB/c mice (4–5 weeks old, 22–26 g, male) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and all animal procedures were approved and compiled with the guidelines of the Institutional Animal Care Committee of China Medical University. The nude mice were housed in a quarantine room for inspection for 2 days before the study. All mice were fed ad libitum and given tap water. Mice were observed daily for the following 3 weeks for tumor formation. The mice were sacrificed on the 28th day after inoculation and the primary tumors were excised and weighed. Tumor volumes were calculated and mouse body weight were measured every other day.

Clinical samples and immunohistochemistry (IHC)

Thirty-four fresh HCC specimens were collected for determining protein levels of USP14 from First Hospital of China Medical University. Tissue microarrays (TMA) from archival formalin-fixed paraffin-embedded (FFPE) resection specimens consisted of 90 pairs of HCC and their adjacent non-tumorous liver tissues were purchased from Outdo Biotech Co. Ltd. None of the patients had received radiotherapy or chemotherapy before surgery. All samples were anonymous. This project was approved by the Institute Research Ethics Committee of the above two institutions. The clinical implication of USP14 was further determined in UALCAN (http://ualcan.path.uab.edu/index.html), an interactive web portal, to perform in-depth analyses of TCGA transcriptome data, and Human Protein Atlas (www.proteinatlas.org) to compare protein expression of USP14 in HCC with normal liver samples. The prognostic value of the USP14 gene in overall survival and relapse-free survival were analyzed by using Kaplan–Meier Plotter (http://kmplot.com/analysis/) with a auto-select best cutoff.

Tissues were fixed with 10% neutral formalin, embedded in paraffin, and 4 μm thick sections were prepared. In brief, immunohistochemistry (IHC) staining was performed as follows. The sections were deparaffinized, hydrated, and soaked in 3% H2O2 for 15 min at room temperature, and subsequently incubated with anti-USP14 (1:200, sc-39800, Santa Cruz Biotechnology), anti-HIF-1α (1:50, 20960-1-AP, Proteintech) antibodies, and anti-Ki67 (1:200, sc-23900, Santa Cruz Biotechnology) antibodies at 4 °C overnight. The slides were incubated with biotinylated goat anti-rabbit antibodies for 1 h and stained with diaminobenzidine (DAB; Maixin Biotechnology, Fuzhou, China), followed by counterstaining with hematoxylin (Maixin Biotechnology).

IHC staining was performed on an HCC tissue microarray (TMA). Stained sections were evaluated in a blinded manner without prior knowledge of the clinical information using the German immunoreactive score, Immunoreactive-Score (IRS). Briefly, the IRS assigns sub-scores for immunoreactive distribution (0–3) and intensity (0–3), then multiplies them to yield the IRS score. The percent positivity was scored as "0" (<5%), "1" (5–25%), "2" (25–50%), "3" (50–75%), "4" (>75%). The staining intensity was score as "0" (no staining), "1" (weakly stained), "2" (moderately stained), and "3" (strongly stained). The final USP14 expression score was calculated with the value of percent positivity score plus staining intensity score, which ranged from 0–12. We estimated IRS by averaging the values in three fields at ×200 magnification for each specimen. The scores were performed by two independent investigators. The median IHC score of 6.0 was chosen as the cut-off value to define the high and low expression.

Statistical analysis

The data of all experiments were analyzed by the Statistical Product and Service Solutions (SPSS) (25.0) statistical software program. Data were presented from three independent experiments. The relationship between USP14 expression and clinical features of HCC was assessed by the Chi-squared test. Data described as mean ± SD and Student’s t-test or one-way ANOVA were used to determine differences among groups. Survival curves were estimated by the Kaplan–Meier method and compared by a log-rank test. P-value less than 0.05 was considered statistically significant.

DATA AVAILABILITY

All data generated or analyzed during this study are included in this published article and its supplementary information files. The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Worms MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010;42:530–39.
3. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15:5–13.
4. Ma Y, Fu Q, del Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 2015;3:83–92.
5. Lis Y, Peet DJ. Turn me on: regulating HIF transcriptional activity. Cell Death Differ. 2008;15:642–9.
6. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharm Sci. 2011;33:207–14.
7. Wigerup C, Pahlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharm Ther. 2016;164:152–69.
8. Robinson CM, Ohh M. The multifaceted von Hippel-Lindau tumour suppressor protein. FEBS Lett. 2014;588:2704–11.
9. Ling S, Shan Q, Zhan Q, Ye Q, Liu P, Xu S, et al. USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1alpha/USP22 positive feedback loop upon TP53 inactivation. Gut. 2019;68:1322–34.
10. Shi M, Dai WQ, Jia RR, Zhang QH, Wei J, Wang YG, et al. APC(CDC20)-mediated degradation of PHD3 stabilizes HIF-1α and promotes tumorigenesis in hepatocellular carcinoma. Cancer Lett. 2021;496:144–55.
11. Hu M, Li P, Song L, Jeffrey PD, Chenova TA, Wilkinson KD, et al. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J. 2005;24:3747–56.
12. Komander D, Clague MJ, Urbé S. Breaking the chains: structure and function of the deubiquitinas. Nat Rev Mol Cell Biol. 2009;10:550–63.
13. Hoeller D, Díick I. Targeting the ubiquitin system in cancer therapy. Nature. 2009;458:438–44.
14. Lee B-H, Lee MJ, Park S, Oh D-C, Elsasser S, Chen P-C, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010;467:179–84.
15. Ma YS, Wang XF, Yu F, Wu TM, Liu JB, Zhang YJ, et al. Inhibition of USP14 and UCH37 deubiquitinating activity by b-AP15 as a potential therapy for tumors with p53 deficiency. Signal Transduct Target Ther. 2020;5:30.
16. Xia X, Huang C, Liao Y, Liu J, Ye, Guo Z, et al. Inhibition of USP14 enhances the sensitivity of breast cancer to enalaprilat. J Exp Clin Cancer Res. 2019;38:220.
17. Liu B, Jiang S, Li M, Xiong X, Zhu M, Li D, et al. Proteome-wide analysis of USP14 substrates reveals its key role in hepatocellular carcinoma via stabilisation of FASN. Nat Commun. 2018;9:4770.

18. Wang Y, Jiang Y, Ding S, Li J, Song N, Ren Y, et al. Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade. Cell Res. 2018;28:1186–94.

19. Lee BH, Lee MJ, Park S, Oh DC, Elssasser S, Chen PC, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010;467:179–84.

20. Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020;21:268–83.

21. Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GL. Short-term anti-vascular endothelial growth factor treatment elicits vasogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res. 2013;31:16.

22. Zhang JG, Zhou HM, Zhang X, Mu W, Hu JN, Liu GL, et al. Hypoxic induction of vasogenic mimicry in hepatocellular carcinoma: role of HIF-1 alpha, RhoA/ROCK and Rac1/PAK signaling. BMC Cancer. 2020;20:32.

23. Li W, Zong S, Shi Q, Li H, Xu J, Hou F. Hypoxia-induced vasogenic mimicry formation in human colorectal cancer cells: involvement of HIF-1α, Claudin-4, and E-cadherin and Vimentin. Sci Rep. 2016;6:37534.

24. Mariantis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasogenic mimicry. Am J Pathol. 1999;155:739–52.

25. Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia. 2015;3:83–92.

26. Keenwon SR. Defining normoxia, physiologic hypoxia and tumors-implications for treatment response. Br J Radiol. 2014;87:20130676.

27. Keith B, Johnson RS, Simon MC, HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;11:29–22.

28. Hu F, Deng X, Yang X, Jin H, Gu D, Lv X, et al. Hypoxia upregulates Rab11-family interacting protein 4 through HIF1alpha to promote the metastasis of hepatocellular carcinoma. Oncogene. 2015;34:6007–17.

29. Hirota K, Senemaza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006;59:15–26.

30. Mendez-Blanco C, Fondevilla F, Garcia-Palomo A, Gonzalez-Gallejo J, Mauriz JL. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med. 2018;50:134.

31. Liao Y, Liu N, Hua X, Cai J, Xia X, Wang X, et al. Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor. Cell Death Dis. 2017;8:e2585.

32. Liao Y, Xia X, Liu N, Cai J, Guo Z, Li Y, et al. Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. Oncogene. 2018;37:1896–910.

33. Li Y, Huang J, Zeng B, Yang D, Sun J, Yin X, et al. PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation. Cancer Lett. 2018;430:109–22.

34. Yu F, Liu JB, Wu ZJ, Xie WT, Zhong XJ, Hou LK, et al. Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14. Cancer Lett. 2018;427:74–84.

35. Huang G, Li L, Zhou W, USP14 activation promotes tumor progression in hepatocellular carcinoma. Oncol Rep. 2015;34:2917–24.

36. Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology. 2004;127:551–555.

37. Haq S, Ramakrishna S. Deubiquitylation of deubiquitylases. Open Biol. 2017;7:170016.

38. Swatek KN, Komander D. Ubiquitin modifications. Cell Res. 2016;26:399–422.

39. Grice GL, Nathan JA. The recognition of ubiquitinated proteins by the proteasome. Cell Mol Life Sci. 2016;73:5497–506.

40. Ni X, Kou W, Gu J, Wei P, Wu X, Peng H, et al. TRAF6 directs FOXP3 localization and facilitates regulatory T-cell function through K63-linked ubiquitination. EMBO J. 2019;38:e99766.

41. Wang S, Zhong X, Wang C, Luo H, Lin L, Sun H, et al. USP22 positively modulates ERalpha action via its deubiquitinase activity in breast cancer. Cell Death Differ. 2020;27:313–45.

42. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays. 2004;26:262–9.

43. Chen F, Fang Y, Zhao R, Le J, Zhang B, Huang R, et al. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma. Eur J Med Chem. 2019;179:916–35.

44. Zhai B, Sun X-Y. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol. 2013;5:345–52.

ACKNOWLEDGEMENTS

We appreciate Dr. Yunlong Huo and Dr. Tao Wen for helpful technique assistance in IHC experiments. We thank Dr. Jia Liu for kind help for mouse model culture. We are grateful to the staff of the animal facility in China Medical University for assistance for Mice Xenograft experiments.

AUTHOR CONTRIBUTIONS

Y.Z., C.L., S.W. designed the study; C.L., S.W., C.W. performed the experiments; K.Z., Y.M. conducting the experiments; C.L., L.L., C.W., K.Z., Y.M., G.S., S.W. analyzed the data; Y.Z. and C.L. wrote the article; Y.L. contributed to the drafting of the paper; all authors approved the final version of the paper.

FUNDING

The study was supported by the National Natural Science Foundation of China [31871286 for Yue Zhao, 81872015 for Shengli Wang, 81702800 for Renlong Zhu]; 973 Program Grant from the Ministry of Science and Technology of China [2013CB945201]; Ministry of Education fund innovation team [IRT 13011]; Foundation for Special Professor of Liaoning Province for Yue Zhao (the 5th batch).

COMPETING INTERESTS

The authors declare no competing interests.

ETHICS STATEMENT

Animal researches were executed in compliance with the Institutional Animal Use and Care Committee of China Medical University. Clinical samples were approved by the Institute Research Ethics Committee of First Hospital of China Medical University and Outdo Biotech Co. Ltd.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-00489-6.

Correspondence and requests for materials should be addressed to Y.Z.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021